• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Astellas to Invest More than $350M in New Ireland Facility


Financial commitment is intended to benefit development and commercialization of new products.

Facility Mockup. Image Credit: Astellas

Facility Mockup. Image Credit: Astellas

Astellas Pharma Inc. intends to submit a planning application to build a new state-of-the-art facility, at an approximate cost of $352 million in Tralee, a town in Ireland’s County Kerry. The investment is expected to expand the pharma company’s capacity and capabilities for aseptic drug products, reinforce stable production for global supply, while also accelerating the development and commercialization of innovative antibody drugs and other new products.

The facility will be based on the Industrial Development Authority's (IDA) greenfield site in Kerry Technology Park, Tralee, bringing highly specialized engineering, science and technology roles to the region.

"This announcement from Astellas is excellent news for the South West region and indeed Ireland,” says Michael Lohan, CEO at IDA. “Astellas already has a presence in both Kerry and Dublin … adding a new state-of-the-art aseptic drug product facility, underscores the strategic importance Ireland plays in Astellas' global operations. The new facility in Tralee will be built with sustainability at its core and will showcase Ireland and our regional attractiveness as a location for investment."

Related Videos
Related Content